What Is Melanotan II?
Melanotan II (MT-II) is classified as a melanocortin agonist peptide. MC4R activation. Non-selectively activates melanocortin receptors to stimulate melanin production, suppress appetite, and increase sexual arousal.
It is extensively evaluated in laboratory and clinical settings for its potential to drive tanning, libido enhancement. Researchers target Melanotan II for its ability to interact with specific cellular and molecular pathways, making it a compound of significant interest across multiple therapeutic domains.
Nausea common; research-only. SIGNIFICANT SAFETY CONCERNS: changes to moles, elevated BP. Actively warned against by FDA/TGA.
How Does Melanotan II Work?
MC4R activation. Non-selectively activates melanocortin receptors to stimulate melanin production, suppress appetite, and increase sexual arousal.
At the molecular level, Melanotan II operates through pathways characteristic of the Melanocortin Agonist class. By interacting with target receptors and downstream signaling cascades, the compound initiates biological responses associated with tanning, libido enhancement.
Expected Research Timeline
Weeks 2–4
Significant skin pigmentation; libido effects
Long-Term
Persistent tan maintained with UV exposure; long-term safety concerns with mole changes
What Does the Research Say?
The following are key findings from peer-reviewed studies on Melanotan II, indexed on PubMed and equivalent databases:
[1]Melanotan II tanning and erectile effects Phase I
Dorr et al. (J. Investigative Dermatol.): Phase I trial in normal male volunteers confirming tanning activity and spontaneous penile erections. Side effects: nausea, somnolence.
Evidence: moderate[2]Melanotan II as potent initiator of penile erection
Wessells et al. (J. Urology): Double-blind study showing MT-II initiates erection in men with erectile dysfunction even without sexual stimulation.
Evidence: moderate[3]Melanotan II as skin cancer chemopreventive peptide
Hadley & Dorr (Peptides): Review of MT-II as potential chemopreventive agent for UV-induced skin cancer through enhanced eumelanin synthesis.
Evidence: preclinical[4]Development of selective MC4R agonists from Melanotan II
Hruby et al. describe development of functionally selective melanocortin receptor agonists derived from MT-II to separate desired from unwanted pharmacological effects.
Evidence: preclinicalSafety & Side Effects
Nausea common; research-only. SIGNIFICANT SAFETY CONCERNS: changes to moles, elevated BP. Actively warned against by FDA/TGA.
| Side Effect | Incidence | Severity |
|---|---|---|
| Nausea | ~45% of users | moderate |
| Facial flushing | ~30% of users | mild |
| Fatigue | ~15% of users | mild |
| Spontaneous erections (men) | ~20% of men | mild |
| Mole changes (darkening) | Variable | uncommon |
FDA Status: Not Approved for Human Therapeutic Use
Melanotan II is not currently FDA-approved for human use. It is available for research purposes only. Always consult a licensed healthcare provider.
How Is Melanotan II Used?
Route
SubQ
Dose Range
250–250 mcg
Frequency
7x/wk
Cycle
4–4 wk
Timing: Any time
Notes: Loading: 250mcg/day for 7-10 days. Maintenance: as needed for UV exposure. START LOW.
All dosing information reflects parameters reported in published research literature and is not intended as clinical guidance. Usage of any peptide should be supervised by a qualified healthcare professional.
Melanotan II vs. Related Compounds
| Compound | Primary Use |
|---|---|
| Melanotan II(this page) | Tanning, libido enhancement |
| PT-141 | Sexual arousal, libido |
Where to Source Melanotan II for Research
Purchasing ultra-high purity, laboratory-grade peptides is critical for verifiable research. We only recommend vendors providing independent, third-party HPLC Certificates of Analysis (COA).
Disclosure: PeptiDex may earn a commission from purchases. This does not affect our recommendations. We exclusively feature vendors that pass our strict quality verification protocols.
Frequently Asked Questions
What is Melanotan II?
Melanotan II is a melanocortin agonist peptide. MC4R activation. Non-selectively activates melanocortin receptors to stimulate melanin production, suppress appetite, and increase sexual arousal.
What are the primary research benefits of Melanotan II?
Published research identifies primary mechanisms targeting: Tanning, libido enhancement. These findings come from 4+ peer-reviewed studies indexed in our database.
What is the half-life of Melanotan II?
In published pharmacokinetic data, Melanotan II demonstrates a half-life of approximately 1 hour.
Is Melanotan II FDA approved?
Melanotan II is not currently FDA-approved for human therapeutic use. It is classified as a research compound and is studied under investigational protocols. Always consult a healthcare provider.
What are common side effects of Melanotan II?
Reported side effects in published literature include Nausea (~45% of users), Facial flushing (~30% of users), Fatigue (~15% of users), Spontaneous erections (men) (~20% of men), Mole changes (darkening) (Variable). Most are classified as moderate in severity.
How is Melanotan II administered?
In research settings, Melanotan II is typically administered via SubQ. Loading: 250mcg/day for 7-10 days. Maintenance: as needed for UV exposure. START LOW.
Sources
- Melanotan II tanning and erectile effects Phase I. View on PubMed
- Melanotan II as potent initiator of penile erection. View on PubMed
- Melanotan II as skin cancer chemopreventive peptide. View on PubMed
- Development of selective MC4R agonists from Melanotan II. View on PubMed